Mapping the Brain While on Psychedelics with Manesh Girn
Psychedelic neuroscientist Manesh Girn talks about his research into neuroimaging of the brain while subjected to psychedelic states and more.
Similar Posts
Meet Bright Minds: The NEXT GEN Psychedelics Company Tackling Pain, Depression and MORE (DRUG/BMBIF)
In today’s episode of the Psychedelic Spotlight Podcast, James Hallifax from the Psychedelic Investor YouTube Channel interviews Ian McDonald, CEO of Bright Minds BioScience. For any investors out there, Bright Minds ticker symbol is DRUG on the Canadian CSE and BMBIF on the American OTC market.
In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. Bright Minds is a company working on second and third generation psychedelics to treat a variety of ailments including depression, PTSD, epilepsy, addiction and more. The driving philosophy is that while classic psychedelics such as psilocybin and LSD do show great potential to be used in a therapy setting to treat mental health issues, the compounds also have limitations.
At Bright Minds, the goal is to engineer completely new compounds, often based on the structure of classical psychedelics, that keep the benefits of said drugs while doing away with potential negatives. Important to note is that while psychedelic derived drugs are a focus of the company, they also are creating non-psychedelic compounds for a variety of ailments, including different forms of addiction.
In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
I had a blast in this interview, and I know you will find it fascinating! Enjoy!
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).
#BrightMinds #ThePsychedelicInvestor #PsychedelicStocks
Is Ketamine Therapy an Effective Treatment for Alcohol Use Disorder? A New Phase 2 Study Says YES!
Is ketamine therapy an effective treatment for alcohol use disorder?…
Interview With Lauren Taus
In this episode of the Psychedelic Spotlight podcast we speak with Lauren Taus who is the Founder of INBodied Life, who’s focus is on integrating modern science and ancient wisdom to support transformation.
NEW MindMed teaming up With Pfizer, J&J and Johns Hopkins on Digital Medicines? (MNMD, PFE, JNJ)
As technological change revolutionizes medicine and healthcare, how do we ensure that no-one, particularly members of vulnerable groups, get left behind?
This is the question that companies like MindMed (MNMD, MMED) , Johnson and Johnson (JNJ), and Pfizer(PFE) , as well as government organizations like the FDA, and universities like Johns Hopkins are trying to answer through collaborating with each other in a forum called The Digital Health Measurement Collaborative Community, or DATAcc.
Useful links:
https://datacc.dimesociety.org/
https://thecannabisstock.com/2021/08/03/mindmed-joins-digital-medicine-society-to-improve-health-outcomes-and-equity-using-technology/
https://www.prnewswire.com/news-releases/healthcare-leaders-collaborate-on-digital-inclusion-initiatives-301341678.html
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #JNJ #Pfizer
Psychedelic Spotlight Interview with Douglas K. Gordon
In this episode of the Psychedelic Spotlight podcast, we connect…
Interview With Joshua White
Fireside Project’s Co-Founder and Director, Joshua White, speaks about the creation and the future of the organization.